我失去了三個四十來歲的朋友，
https://twitter.com/Rectitude2022/status/1560818079310946304
https://twitter.com/Rectitude2022
https://expose-news.com/2022/08/16/us-gov-covid-vaccination-risk-cancer-143233-percent/
https://twitter.com/wenjiebc/status/1561842641729474563
伊維菌素髮明者
Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
結論： 基於 18 項 COVID-19 伊維菌素隨機對照治療試驗的薈萃分析發現，死亡率、臨床恢復時間和病毒清除時間顯着降低，具有統計學意義。此外，許多對照預防試驗的結果表明，經常使用伊維菌素可顯着降低感染 COVID-19 的風險。最後，許多伊維菌素分發活動導致全人群發病率和死亡率迅速下降的例子表明，已經確定了一種在 COVID-19 的所有階段都有效的口服藥物。
The evidence base for ivermectin against COVID-19 To date, the efficacy of ivermectin in COVID-19 has been supported by the following: Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue, and others.9–17Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue through several observed and proposed mechanisms.18Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation.37–39Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses.31,32Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients.40–45Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms.45,49–52,61,62Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalized patients.45,51,53,63–66Ivermectin reduces mortality in critically ill patients with COVID-19.45,53,63Ivermectin leads to temporally associated reductions in case fatality rates in regions after ivermectin distribution campaigns.48The safety, availability, and cost of ivermectin are nearly unparalleled given its low incidence of important drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered.75The World Health Organization has long included ivermectin on its “List of Essential Medicines.”伊維菌素對抗 COVID-19 的證據基礎 迄今為止，伊維菌素在 COVID-19 中的療效得到以下支持： 自 2012 年以來，多項體外研究表明，伊維菌素可抑制多種病毒的複製，包括流感、寨卡病毒、登革熱病毒等。9 - 17伊維菌素通過幾種觀察到和提出的機制抑制 SARS-CoV-2 複製和與宿主組織的結合。18伊維菌素具有有效的抗炎特性，體外數據表明對細胞因子產生和核因子-κB (NF-κB) 轉錄的顯着抑制，核因子-κB (NF-κB) 是最有效的炎症介質。37 – 39當感染 SARS-CoV-2 或類似冠狀病毒時，伊維菌素可顯着降低病毒載量並保護多種動物模型免受器官損傷。31 , 32伊維菌素可防止接觸受感染患者的人傳播和發展 COVID-19 疾病。40 – 45伊維菌素可加速症狀後早期治療的輕度至中度疾病患者的康復並防止病情惡化。45 , 49 – 52 , 61 , 62伊維菌素可加速住院患者的康復並避免入住 ICU 和死亡。45 , 51 , 53 , 63 – 66伊維菌素可降低 COVID-19 重症患者的死亡率。45 , 53 , 63在伊維菌素分發活動之後，伊維菌素導致各地區病死率的時間相關降低。48伊維菌素的安全性、可用性和成本幾乎是無與倫比的，因為其重要藥物相互作用的發生率很低，並且在近 40 年的使用和數十億劑的給藥中僅觀察到輕微和罕見的副作用。75世界衛生組織長期以來一直將伊維菌素列入其“基本藥物清單”。
經過一段時間的討論後，根據標準的 WHO 指南制定流程，對伊維菌素數據的多個方面進行了投票。小組發現伊維菌素對生存影響的證據確定性很強，他們建議無條件採用用於 COVID-19 的預防和治療。 綜上所述，根據本次審查中提供的全部試驗和流行病學證據，以及 Unitaid/WHO 對治療 RCT 的薈萃分析的初步結果和國際 BIRD 會議的指南建議，伊維菌素應在全球範圍內系統地部署在預防和治療 COVID-19 方面。 The Panel found the certainty of evidence for ivermectin's effects on survival to be strong and they recommended unconditional adoption for use in the prophylaxis and treatment of COVID-19. In summary, based on the totality of the trials and epidemiologic evidence presented in this review along with the preliminary findings of the Unitaid/WHO meta-analysis of treatment RCTs and the guideline recommendation from the international BIRD conference, ivermectin should be globally and systematically deployed in the prevention and treatment of COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/
Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
結論：
中等質量證據發現，使用伊維菌素可以大幅減少 COVID-19 死亡人數。在臨床過程早期使用伊維菌素可能會減少進展為嚴重疾病的人數。明顯的安全性和低成本表明，伊維菌素可能對全球SARS-CoV-2大流行產生重大影響。
DISCUSSION The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit. Our certainty of evidence judgment was consolidated by the results of trial sequential analyses, which show that the required IS has probably already been met. Low-certainty evidence on improvement and deterioration also support a likely clinical benefit of ivermectin. Low-certainty evidence suggests a significant effect in prophylaxis. Overall, the evidence also suggests that early use of ivermectin may reduce morbidity and mortality from COVID-19. This is based on (1) reductions in COVID-19 infections when ivermectin was used as prophylaxis, (2) the more favorable effect estimates for mild to moderate disease compared with severe disease for death due to any cause, and (3) on the evidence demonstrating reductions in deterioration. 討論 研究結果中度確定地表明，伊維菌素治療 COVID-19 提供了顯着的生存益處。試驗順序分析的結果鞏固了我們對證據判斷的確定性，這表明可能已經滿足了所需的 IS。關於改善和惡化的低質量證據也支持伊維菌素可能的臨床益處。低質量證據表明在預防方面有顯着效果。總體而言，證據還表明，早期使用伊維菌素可能會降低 COVID-19 的發病率和死亡率。這是基於 (1) 使用伊維菌素預防時 COVID-19 感染減少，(2) 與嚴重疾病相比，由於任何原因導致的死亡，輕度至中度疾病的效果估計更有利， 本綜述中嚴重不良事件的證據被評為低質量，部分原因是事件太少而無法達到統計學意義。最近對寄生蟲感染患者使用伊維菌素進行系統評價的證據表明，以常規劑量（0.2 或 0.4 mg/kg）施用伊維菌素是安全的，並且在更高劑量下可能是安全的。7,116世界衛生組織最近一份關於伊維菌素用於疥瘡的文件發現，伊維菌素的不良事件主要是輕微和短暫的。
https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx
https://www.nfscdict.com/%E9%9D%92%E8%92%BF%E7%B4%A0
https://www.nfscdict.com/%E9%9D%92%E8%92%BF%E7%B4%A0
來源鏈接:
https://twitter.com/YingJie22739040/status/1561995376541908992
2023年1月22日星期日 兔年春節
| 
